May 25, 2023
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
Evaxion today unveils the technology behind its novel, proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.today unveils the technology behind its novel, proprietary genetic adjuvant developed to enhance the effectiveness of DNA and mRNA vaccines for infectious diseases and cancer.
May 11, 2023
DNA immunization with in silico predicted T-cell epitopes protects against lethal SARS-CoV-2 infection in K18-hACE2 mice
Authors: Gry Persson, Katherine H. Restori, Julie Hincheli Emdrup, Sophie Schussek, Michael Schantz Klausen, McKayla J. Nicol, Bhuvana Katkere, Birgitte Rønø, Girish Kirimanjeswara & Anders Bundgaard Sørensen
Apr 18, 2023
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints
Evaxion presented promising clinical data from its Phase 1/2a first-in-human study of its DNA-based personalized cancer immunotherapy, EVX-02 in combination with the checkpoint inhibitor nivolumab
Apr 13, 2023
Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform
Evaxion today announced the successful publication in Frontiers of Immunology of preclinical data demonstrating the effectiveness of its proprietary AI-driven viral vaccine discovery platform. The presented preclinical study was conducted in collaboration with associate professor Girish Kirimanjeswara, Pennsylvania State University, US.
Mar 28, 2023
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
By optimizing the strategy around EVX 01, we can deliver the Phase 2b interim data in Q4 2023 as planned while deploying important clinical resources to EVX-03, where we are likely to be first in the world bringing a personalized ERV-immunotherapy to cancer patients. In addition, the focus on our core will extend our cash runway towards the end of the year.
Mar 27, 2023
Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy
Authors: Christian Garde, Michail A Pavlidis, Pablo Garces, Emma J Lange, Sri H Ramarathinam, Mateo Sokac, Kirti Pandey, Pouya Faridi, Johanne Ahrenfeldt, Shanzou Chung, Stine Friis, Daniela Kleine-Kohlbrecher, Nicolai J Birkbak, Jens V Kringelum, Birgitte Rono, Anthony W Purcell, Thomas Trolle
Mar 23, 2023
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy
This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.